Charlotte Sorieul

Charlotte Sorieul

Auto-generated profile, based on publicly available information

Charlotte Sorieul

Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in Expert Review of Vaccines
Verified
Journal Article
Open access
CSCharlotte Sorieul
Charlotte Sorieul
MDMarta Dolce
Marta Dolce
MRMaria Rosaria Romano
Maria Rosaria Romano
JCJeroen Codée
Jeroen Codée
RARoberto Adamo
Roberto Adamo
Antimicrobial resistance (AMR) is responsible for the death of millions worldwide and stands as a major threat to our healthcare systems, which are heavily reliant on antibiotics to fight bacterial infections. The development of vaccines against the main pathogens involved is urgently required as prevention remains essential against the rise of AMR. A systematic research review was conducted on MEDLINE database focusing on the six AMR pathogens defined as ESPAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli), which are considered critical or high priority pathogens by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). The analysis was interseacted with the terms carbohydrate, glycoconjugate, bioconjugate, glyconanoparticle and multiple presenting antigen system vaccines. Glycoconjugate vaccines have been successful in preventing meningitis and pneumoniae, and there are high expectations that they will play a key role in fighting AMR. We herein discuss the recent technological, preclinical and clinical advances, as well as the challenges associated with the development of carbohydrate-based vaccines against leading AMR bacteria, with focus on the ESKAPE pathogens. The need of innovative clinical and regulatory approaches to tackle these targets is also highlighted.

10 February 2022 in Chemical Science
Verified
Journal Article
Open access
PDF file
FCFilippo Carboni
Filippo Carboni
AKAnnabel Kitowski
Annabel Kitowski
CSCharlotte Sorieul
Charlotte Sorieul
DVDaniele Veggi
Daniele Veggi
MMMarta C. Marques
Marta C. Marques
RARoberto Adamo
Roberto Adamo
The introduction of glycoconjugate vaccines marks an important point in the fight against various infectious diseases.

27 March 2026 in Science Advances
Verified
Journal Article
Open access
YSYao Shi
Yao Shi
GWGoran Widmalm
Goran Widmalm
CSCharlotte Sorieul
Charlotte Sorieul
TRThomas J. Roodsant
Thomas J. Roodsant
JRJeffrey S. Rush
Jeffrey S. Rush
NSNina M. van Sorge
Nina M. van Sorge
Streptococcus suis is a largely neglected but emerging bacterial zoonotic pathogen of global concern for animal welfare, antibiotic resistance development, and human health. No effective vaccines are now available. Here, we identified and characterized the function and structure of two cell wall polysaccharide variants in pathogenic S. suis strains using genetic deletion and (heterologous) complementation, lectin staining, glycan composition analysis, and specialized NMR spectroscopy. Both glycan variants were anionic polymers that differed in the presence of glucose in the side chain as a result of allelic variation in a glycosyltransferase gene. Deletion of this variable glycosyltransferase revealed an identical glycan “core” and affected S. suis morphology and lysozyme resistance. Immunization of pigs with this core domain elicited antibodies that recognized antigenically diverse pathogenic S. suis strains and induced complement deposition on encapsulated pathogenic S. suis strains. This study provides valuable insights for developing next-generation glycoconjugate vaccines, whereby a single-glycan target could protect against the emerging zoonotic pathogen S. suis .

3 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
YSYao Shi
Yao Shi
GWGoran Widmalm
Goran Widmalm
CSCharlotte Sorieul
Charlotte Sorieul
TRThomas J. Roodsant
Thomas J. Roodsant
JRJeffrey S. Rush
Jeffrey S. Rush
NSNina M. van Sorge
Nina M. van Sorge
Streptococcus suis is a largely neglected but emerging bacterial zoonotic pathogen of global concern for animal welfare, antibiotic resistance development and human health. No effective vaccines are currently available. Here, we identified and characterized the function and structure of two cell wall polysaccharide variants in pathogenic S. suis strains using genetic deletion and (heterologous) complementation, lectin staining, glycan composition analysis and specialized NMR spectroscopy. Both glycan variants were anionic polymers that differed in the presence of glucose in the side-chain as a result of allelic variation in a glycosyltransferase gene. Deletion of this variable glycosyltransferase revealed an identical glycan ‘core’ and affected S. suis morphology and lysozyme resistance. Immunization of pigs with this core domain induced antibodies recognizing a wide range of antigenically-diverse pathogenic S. suis strains. This study provides new insights for developing next-generation glycoconjugate vaccines, whereby a single-glycan target could protect against the emerging zoonotic pathogen S. suis .